Advertisement

Document › Details
Thermo Fisher Scientific Inc.. (3/16/18). "Press Release: Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany". Rheinfelden.
![]() |
Organisation | Thermo Fisher (Group) |
![]() |
Product | laboratory equipment and instruments |
Product 2 | clinical research services | |
New site will support complex clinical research and bring more than 200 new jobs to community
Thermo Fisher Scientific announced today it is expanding its footprint in the European Union and investing $35 million in a state-of-the-art pharma services supply chain facility in Rheinfelden (Baden) Germany. Company representatives joined Mayor Eberhardt at the Rheinfelden council meeting to unveil the details of the project earlier today.
The new facility will leverage the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials in support of complex clinical research and so meet the growing needs of customers. The facility will be scalable for mixed-use space and provide a strategic logistical location for shipping either by road or air.
Mayor Eberhardt acknowledged local support for the project stating, "We are looking forward to partnering with Thermo Fisher Scientific to bring this new facility to life in our community which will create significant opportunity for jobs in the expanding life sciences segment. We are confident their investment will benefit our local economy and create greater opportunities for our citizens."
The company expects to start construction in Q4' 2018 for the 8,000 square meter facility at the 26,000 square meter site with an anticipated completion within 12 to 18 months. Once complete, this new facility will provide up to 200 new jobs locally. The investment includes the option for additional expansion with the potential for doubling the footprint.
"This is an exciting time for our business, and it reinforces our commitment to best serve our clients globally. By creating a best-in-class supply chain facility in the EU, we open new opportunities to support client and patient need," said Astrid Frank, Vice President and General Manager, Europe, Fisher Clinical Services.
The company's decision to expand is in response to a growing demand for global clinical supply services, worldwide. The new facility will also serve to address GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019. This GMP/GDP facility builds on the company's existing footprint of 20 purpose-built cGMP facilities globally.
Thermo Fisher's Pharma Services develops unique solutions and business models to help customers manage the clinical development process and provides flexible manufacturing options to address client needs in an evolving marketplace.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $20 billion and more than 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Media Contact Information:
Name: Mari Mansfield
Title: Senior Director, External Communication
Phone: (919) 632-4712
Email: mari.mansfield@patheon.com
Record changed: 2018-03-22 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Thermo Fisher (Group)
- [1] Owlstone Medical Ltd.. (11/7/19). "Press Release: Owlstone Medical Enters Partnership with Thermo Fisher Scientific to Advance Early Disease Detection Using Non-invasive Breath Biopsy". Cambridge....
- [2] Dalhousie University. (10/7/19). "Press Release: Molly Appeal to Help Fund Orbitrap Fusion, Boosting Cancer, Brain, Immunity Research"....
- [3] Solentim Ltd.. (10/1/19). "Press Release: Dr Mark Truesdale Joins Solentim as New Chief Marketing Officer". Bournemouth....
- [4] Thermo Fisher Scientific Inc.. (9/25/19). "Press Release: Thermo Fisher Scientific Prices Offering of Senior Notes". Waltham, MA....
- [5] Thermo Fisher Scientific Inc.. (6/10/19). "Press Release: Thermo Fisher Scientific and Roper Technologies Announce Termination of Gatan Acquisition. Existing Supply Agreement Remains Intact". Waltham, MA & Sarasota, FL....
- [6] Thermo Fisher Scientific Inc.. (6/6/19). "Press Release: Thermo Fisher Scientific Acquires HighChem, Provider of Mass Spectrometry Software". San José, CA....
- [7] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Announces Agreement Securing Access To Large-scale, Commercial-grade Manufacturing Capacity at Brammer Bio". Brisbane, CA....
- [8] Thermo Fisher Scientific Inc.. (3/24/19). "Press Release: Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing". Waltham, MA & Cambridge, MA....
- [9] Fluidigm Corporation. (3/5/19). "Press Release: Colin McCracken Joins Fluidigm as Chief Commercial Officer". South San Francisco, CA....
- [10] OBN (UK) Ltd.. (2/19/19). "Press Release: OBN Launches New Purchasing Platform to Provide E-Commerce Solution for its Members"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top